GB1582014A - Pteridine compounds - Google Patents
Pteridine compounds Download PDFInfo
- Publication number
- GB1582014A GB1582014A GB13747/77A GB1374777A GB1582014A GB 1582014 A GB1582014 A GB 1582014A GB 13747/77 A GB13747/77 A GB 13747/77A GB 1374777 A GB1374777 A GB 1374777A GB 1582014 A GB1582014 A GB 1582014A
- Authority
- GB
- United Kingdom
- Prior art keywords
- pteridine
- triamino
- hydroxyphenyl
- hydrogen sulphate
- sulphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 125000001042 pteridinyl group Chemical class N1=C(N=CC2=NC=CN=C12)* 0.000 title 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 12
- -1 hydroxyphenyl pteridine hydrogen sulphate Chemical compound 0.000 claims description 12
- XLDULUFMFYKGCS-UHFFFAOYSA-N 2-phenyl-1h-pteridin-4-one Chemical compound N1C2=NC=CN=C2C(=O)N=C1C1=CC=CC=C1 XLDULUFMFYKGCS-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 231100000252 nontoxic Toxicity 0.000 claims description 10
- 230000003000 nontoxic effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 4
- 150000003863 ammonium salts Chemical class 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000001117 sulphuric acid Substances 0.000 claims description 3
- 235000011149 sulphuric acid Nutrition 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000007717 exclusion Effects 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 159000000001 potassium salts Chemical class 0.000 claims 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 32
- 229960001288 triamterene Drugs 0.000 description 25
- 239000000243 solution Substances 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 230000001882 diuretic effect Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 208000004880 Polyuria Diseases 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000002934 diuretic Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical class N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- GAPYKZAARZMMGP-UHFFFAOYSA-N pyridin-1-ium;acetate Chemical compound CC(O)=O.C1=CC=NC=C1 GAPYKZAARZMMGP-UHFFFAOYSA-N 0.000 description 3
- 210000003079 salivary gland Anatomy 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- KMHBCNZKFPKMAF-UHFFFAOYSA-N 3,5-diamino-2-(7-aminopteridin-2-yl)phenol Chemical compound NC1=C(C(=CC(=C1)N)O)C1=NC2=NC(=CN=C2C=N1)N KMHBCNZKFPKMAF-UHFFFAOYSA-N 0.000 description 1
- QNJVMSASTUDLGC-UHFFFAOYSA-N 4-(2,4,7-triaminopteridin-6-yl)phenol Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=C(O)C=C1 QNJVMSASTUDLGC-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 210000001038 distal kidney tubule Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 150000003195 pteridines Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2614738A DE2614738C2 (de) | 1976-04-06 | 1976-04-06 | Diuretisch wirkende Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1582014A true GB1582014A (en) | 1980-12-31 |
Family
ID=5974527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB13747/77A Expired GB1582014A (en) | 1976-04-06 | 1977-03-31 | Pteridine compounds |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4118492A (cg-RX-API-DMAC7.html) |
| JP (1) | JPS52122618A (cg-RX-API-DMAC7.html) |
| DE (1) | DE2614738C2 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2347043A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB1582014A (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252809A (en) * | 1977-01-03 | 1981-02-24 | Rohm Pharma Gmbh | Substituted pteridine compounds and pharmaceutical compositions containing the same |
| DE2815442A1 (de) | 1978-04-10 | 1979-10-18 | Roehm Pharma Gmbh | Rasch wirksame diuretika |
| US4425346A (en) | 1980-08-01 | 1984-01-10 | Smith And Nephew Associated Companies Limited | Pharmaceutical compositions |
| DE3448490C2 (de) * | 1984-04-05 | 1995-04-27 | Roehm Pharma Gmbh | Verwendung von Pteridinderivaten zur Behandlung von Herzarrhythmien |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3081230A (en) * | 1960-09-08 | 1963-03-12 | Smith Kline French Lab | Diuretic and antihypertensive triaminoarylpteridines |
-
1976
- 1976-04-06 DE DE2614738A patent/DE2614738C2/de not_active Expired
-
1977
- 1977-03-29 FR FR7709307A patent/FR2347043A1/fr active Granted
- 1977-03-31 US US05/783,386 patent/US4118492A/en not_active Expired - Lifetime
- 1977-03-31 GB GB13747/77A patent/GB1582014A/en not_active Expired
- 1977-04-06 JP JP3938477A patent/JPS52122618A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS52122618A (en) | 1977-10-15 |
| FR2347043B1 (cg-RX-API-DMAC7.html) | 1979-03-02 |
| US4118492A (en) | 1978-10-03 |
| FR2347043A1 (fr) | 1977-11-04 |
| DE2614738A1 (de) | 1977-10-27 |
| JPS6143329B2 (cg-RX-API-DMAC7.html) | 1986-09-26 |
| DE2614738C2 (de) | 1985-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Plaut et al. | Properties of a subpopulation of T cells bearing histamine receptors. | |
| Bach et al. | Studies on thymus products: II. Demonstration and characterization of a circulating thymic hormone | |
| Darrow | Changes in muscle composition in alkalosis | |
| AU554125B2 (en) | 4(aryl-alkyl)imidazole derivatives | |
| Diczfalusy et al. | Urinary excretion of natural oestrogens in oophorectomized women treated with polyoestradiol phosphate (PEP) | |
| DE68915341T2 (de) | Expektoranz, das ein Hydroxy-alkyl-cystein-Derivat enthält. | |
| GB2110663B (en) | Imidazole derivatives | |
| Fawaz et al. | Mechanism of Action of Mercurial Diuretics II. | |
| GB1582014A (en) | Pteridine compounds | |
| EP0088385A3 (en) | 7-acylamino-3-cephem-4-carboxylic acid derivatives, processes for the preparation of the same and pharmaceutical composition comprising the same | |
| Gershoff et al. | Effect of vitamin B6 and magnesium on renal deposition of calcium oxalate induced by ethylene glycol administration. | |
| Milstone | TAMe esterase activity of blood thrombokinase after repeated electrophoretic fractionations. | |
| ES2003200A6 (es) | Un procedimiento para la preparacion de esteroides aminoglicosidicos. | |
| Ardeman et al. | Studies on Human Gastric Intrinsic Factor OBSERVATIONS ON ITS POSSIBLE ABSORPTION AND ENTEROHEPATIC CIRCULATION | |
| Unkefer et al. | The 5-O-beta-D-galactofuranosyl-containing glycopeptide from Penicillium charlesii. Identification of phosphocholine attached to C-6 of mannopyranosyl residues of the mannan region. | |
| GB1583691A (en) | Benzopyrans | |
| Fawaz et al. | Phosphocreatine content of mammalian cardiac muscle. | |
| Fitch et al. | The metabolism of creatine-1-C 14 by mice with hereditary muscular dystrophy | |
| Whipp et al. | Regulation of aldosterone in the rat effect of oestrous cycle, pregnancy, and sodium status | |
| US3576007A (en) | Water soluble salts of ellagic acid | |
| GB1597882A (en) | Injectable pharmaceutical compositions comprising pteridine derivatives | |
| EP0038572A1 (en) | 1-Nitro-9-hydroxyalkylaminoacridines or their salts | |
| ES8308317A1 (es) | Procedimiento de preparacion de nuevos derivados de 2-fenilmorfolina. | |
| RU94018525A (ru) | Замещенные 2-гидрокси-3[1-(1н-имидазол-4-ил)алкил]-бензолкарбоксимидамиды, способы их получения и фармацевтическая композиция на их основе | |
| Wilkinson et al. | The biological action of substances related to thyroxine. 9. The effect of butyl 4-hydroxy-3: 5-diiodobenzoate on the deiodination of triiodothyronine in the rat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19950331 |